Mylan Laboratories and Barr Pharmaceuticals Tuesday became the second and third drugmakers to receive FDA approval to sell generic versions of Pfizer’s blockbuster antidepressant Zoloft.
Both companies said they would begin shipping the product immediately.
Pfizer lost patent protection on Zoloft last August. Branded Zoloft sales fell 79% in Pfizer’s fourth quarter to $166 million, compared with $808 million in the same period a year earlier.
Teva Pharmaceutical was able to sell the only generic version during the first six months after expiration of Zoloft’s patent, under a federally enforced exclusivity period.